{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:17:13Z","timestamp":1771841833275,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00228-021-03224-8","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T17:53:28Z","timestamp":1634061208000},"page":"215-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China"],"prefix":"10.1007","volume":"78","author":[{"given":"Si-qi","family":"Lyu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-hui","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-8133","authenticated-orcid":false,"given":"Yan-min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"issue":"10","key":"3224_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA et al (2016) 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol 68(10):1082\u20131115. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3224_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J 39(3):213\u2013260. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"key":"3224_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker R, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. New Engl J Med 361:1045. https:\/\/doi.org\/10.1056\/NEJMoa0904327","journal-title":"New Engl J Med"},{"issue":"20","key":"3224_CR4","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"S Wiviott","year":"2007","unstructured":"Wiviott S, Braunwald E, McCabe C et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. New Engl J Med 357(20):2001\u20132015. https:\/\/doi.org\/10.1056\/NEJMoa0706482","journal-title":"New Engl J Med"},{"issue":"9","key":"3224_CR5","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.amjcard.2016.02.012","volume":"117","author":"W Fan","year":"2016","unstructured":"Fan W, Plent S, Prats J et al (2016) Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice[J]. Am J Cardiol 117(9):1439\u20131443. https:\/\/doi.org\/10.1016\/j.amjcard.2016.02.012","journal-title":"Am J Cardiol"},{"issue":"4","key":"3224_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMoa0808227","volume":"360","author":"T Simon","year":"2009","unstructured":"Simon T, Verstuyft C, Mary-Krause M et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events[J]. New Engl J Med 360(4):363\u2013375. https:\/\/doi.org\/10.1056\/NEJMoa0808227","journal-title":"New Engl J Med"},{"issue":"6","key":"3224_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/CIRCGENETICS.114.000669","volume":"7","author":"M Sorich","year":"2014","unstructured":"Sorich M, Rowland A, McKinnon R et al (2014) CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis[J]. Circ Cardiovasc Genet 7(6):895\u2013902. https:\/\/doi.org\/10.1161\/CIRCGENETICS.114.000669","journal-title":"Circ Cardiovasc Genet"},{"issue":"24","key":"3224_CR8","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1001\/jama.2011.1880","volume":"306","author":"MV Holmes","year":"2011","unstructured":"Holmes MV, Perel P, Shah T et al (2011) CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis [J]. JAMA 306(24):2704\u20132714. https:\/\/doi.org\/10.1001\/jama.2011.1880","journal-title":"JAMA"},{"issue":"9749","key":"3224_CR9","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L, James S, Storey R et al (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J]. Lancet 376(9749):1320\u20131328. https:\/\/doi.org\/10.1016\/S0140-6736(10)61274-3","journal-title":"Lancet"},{"issue":"19","key":"3224_CR10","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","volume":"119","author":"J Mega","year":"2009","unstructured":"Mega J, Close S, Wiviott S et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes[J]. Circulation 119(19):2553\u20132560. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.851949","journal-title":"Circulation"},{"key":"3224_CR11","doi-asserted-by":"publisher","unstructured":"Mayer K, Schulz S, Bernlochner I, et al. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry[J]. Thromb Haemost 2014, 112(2):342\u2013351.\u00a0https:\/\/doi.org\/10.1160\/th13-10-0874.","DOI":"10.1160\/th13-10-0874"},{"issue":"5","key":"3224_CR12","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ijcard.2012.05.040","volume":"167","author":"JM Siller-Matula","year":"2013","unstructured":"Siller-Matula JM, Francesconi M, Dechant C et al (2013) Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study[J]. Int J Cardiol 167(5):2018\u20132023. https:\/\/doi.org\/10.1016\/j.ijcard.2012.05.040","journal-title":"Int J Cardiol"},{"issue":"11","key":"3224_CR13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.2011.290","volume":"305","author":"MJ Price","year":"2011","unstructured":"Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial[J]. JAMA 305(11):1097\u20131105. https:\/\/doi.org\/10.1001\/jama.2011.290","journal-title":"JAMA"},{"issue":"22","key":"3224_CR14","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","volume":"367","author":"JP Collet","year":"2012","unstructured":"Collet JP, Cuisset T, Rang\u00e9 G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting[J]. New Engl J Med 367(22):2100\u20132109. https:\/\/doi.org\/10.1056\/NEJMoa1209979","journal-title":"New Engl J Med"},{"issue":"10055","key":"3224_CR15","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","volume":"388","author":"G Cayla","year":"2016","unstructured":"Cayla G, Cuisset T, Silvain J et al (2016) Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial[J]. The Lancet 388(10055):2015\u20132022. https:\/\/doi.org\/10.1016\/S0140-6736(16)31323-X","journal-title":"The Lancet"},{"issue":"10104","key":"3224_CR16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/s0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C et al (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial[J]. The Lancet 390(10104):1747\u20131757. https:\/\/doi.org\/10.1016\/s0140-6736(17)32155-4","journal-title":"The Lancet"},{"issue":"4","key":"3224_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.117.002069","volume":"11","author":"CR Lee","year":"2018","unstructured":"Lee CR, Sriramoju VB, Cervantes A et al (2018) Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention [J]. Circ Genom Precis Med 11(4):e002069. https:\/\/doi.org\/10.1161\/CIRCGEN.117.002069","journal-title":"Circ Genom Precis Med"},{"issue":"9827","key":"3224_CR18","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","volume":"379","author":"JD Roberts","year":"2012","unstructured":"Roberts JD, Wells GA, Le May MR et al (2012) Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial[J]. Lancet 379(9827):1705\u20131711. https:\/\/doi.org\/10.1016\/S0140-6736(12)60161-5","journal-title":"Lancet"},{"issue":"11","key":"3224_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.20452\/pamw.4087","volume":"127","author":"M Tomaniak","year":"2017","unstructured":"Tomaniak M, Koltowski L, Kochman J et al (2017) Can prasugrel decrease the extent of periprocedural myocardial injury during elective percutaneous coronary intervention?[J]. Pol Arch Intern Med 127(11):730\u2013740. https:\/\/doi.org\/10.20452\/pamw.4087","journal-title":"Pol Arch Intern Med"},{"issue":"1","key":"3224_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/circgen.119.002640","volume":"13","author":"S Tuteja","year":"2020","unstructured":"Tuteja S, Glick H, Matthai W et al (2020) Prospective CYP2C19 genotyping to guide antiplatelet therapy following percutaneous coronary intervention: a pragmatic randomized clinical trial [J]. Circ Genom Precis Med 13(1):e002640. https:\/\/doi.org\/10.1161\/circgen.119.002640","journal-title":"Circ Genom Precis Med"},{"issue":"4","key":"3224_CR21","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1016\/j.ijcard.2013.06.014","volume":"168","author":"X Xie","year":"2013","unstructured":"Xie X, Ma YT, Yang YN et al (2013) Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial[J]. Int J Cardiol 168(4):3736\u20133740. https:\/\/doi.org\/10.1016\/j.ijcard.2013.06.014","journal-title":"Int J Cardiol"},{"issue":"17","key":"3224_CR22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","volume":"71","author":"FM Notarangelo","year":"2018","unstructured":"Notarangelo FM, Maglietta G, Bevilacqua P et al (2018) Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes [J]. J Am Coll Cardiol 71(17):1869\u20131877. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.029","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"3224_CR23","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","volume":"381","author":"DMF Claassens","year":"2019","unstructured":"Claassens DMF, Vos GJA, Bergmeijer TO et al (2019) A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI[J]. New Engl J Med 381(17):1621\u20131631. https:\/\/doi.org\/10.1056\/NEJMoa1907096","journal-title":"New Engl J Med"},{"issue":"8","key":"3224_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.2020.12443","volume":"324","author":"NL Pereira","year":"2020","unstructured":"Pereira NL, Farkouh ME, So D et al (2020) Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial[J]. JAMA 324(8):761\u2013771. https:\/\/doi.org\/10.1001\/jama.2020.12443","journal-title":"JAMA"},{"issue":"16","key":"3224_CR25","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/circulationaha.108.791061","volume":"118","author":"SD Wiviott","year":"2008","unstructured":"Wiviott SD, Braunwald E, Angiolillo DJ et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38[J]. Circulation 118(16):1626\u20131636. https:\/\/doi.org\/10.1161\/circulationaha.108.791061","journal-title":"Circulation"},{"issue":"9867","key":"3224_CR26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/s0140-6736(13)60108-7","volume":"381","author":"V Farooq","year":"2013","unstructured":"Farooq V, van Klaveren D, Steyerberg EW et al (2013) Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II[J]. Lancet 381(9867):639\u2013650. https:\/\/doi.org\/10.1016\/s0140-6736(13)60108-7","journal-title":"Lancet"},{"issue":"1","key":"3224_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCINTERVENTIONS.108.809285","volume":"2","author":"JE Tcheng","year":"2009","unstructured":"Tcheng JE, Lim IH, Srinivasan S et al (2009) Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb\/IIIa blockade: findings of the ESPRIT trial[J]. Circ Cardiovasc Interv 2(1):43\u201351. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.108.809285","journal-title":"Circ Cardiovasc Interv"},{"issue":"9","key":"3224_CR28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00228-019-02696-z","volume":"75","author":"PWA Janssen","year":"2019","unstructured":"Janssen PWA, Bergmeijer TO, Vos GA et al (2019) Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI-the POPular Risk Score study[J]. Eur J Clin Pharmacol 75(9):1201\u20131210. https:\/\/doi.org\/10.1007\/s00228-019-02696-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"3224_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038936","volume":"10","author":"DF Hernandez-Suarez","year":"2020","unstructured":"Hernandez-Suarez DF, Melin K, Marin-Maldonado F et al (2020) Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial[J]. BMJ Open 10(8):e038936. https:\/\/doi.org\/10.1136\/bmjopen-2020-038936","journal-title":"BMJ Open"},{"issue":"12","key":"3224_CR30","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"L Bonello","year":"2010","unstructured":"Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J]. J Am Coll Cardiol 56(12):919\u2013933. https:\/\/doi.org\/10.1016\/j.jacc.2010.04.047","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"3224_CR31","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium[J]. Circulation 123(23):2736\u20132747. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.009449","journal-title":"Circulation"},{"issue":"20","key":"3224_CR32","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/cir.0000000000000617","volume":"138","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffe AS et al (2018) Fourth universal definition of myocardial infarction (2018)[J]. Circulation 138(20):e618\u2013e651. https:\/\/doi.org\/10.1161\/cir.0000000000000617","journal-title":"Circulation"},{"issue":"17","key":"3224_CR33","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions[J]. Circulation 115(17):2344\u20132351. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.685313","journal-title":"Circulation"},{"issue":"1","key":"3224_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12872-017-0582-6","volume":"17","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Wang Y, Wu Y et al (2017) Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials[J]. BMC Cardiovasc Disord 17(1):157. https:\/\/doi.org\/10.1186\/s12872-017-0582-6","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"3224_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/09537104.2017.1349306","volume":"29","author":"Z Xing","year":"2018","unstructured":"Xing Z, Tang L, Zhu Z et al (2018) Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials[J]. Platelets 29(6):589\u2013595. https:\/\/doi.org\/10.1080\/09537104.2017.1349306","journal-title":"Platelets"},{"issue":"7","key":"3224_CR36","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/ccd.27949","volume":"93","author":"B Kheiri","year":"2019","unstructured":"Kheiri B, Osman M, Abdalla A et al (2019) CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: a meta-analysis of randomized clinical trials[J]. Catheter Cardiovasc Interv 93(7):1246\u20131252. https:\/\/doi.org\/10.1002\/ccd.27949","journal-title":"Catheter Cardiovasc Interv"},{"issue":"8","key":"3224_CR37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/09537104.2020.1780205","volume":"31","author":"SQ Lyu","year":"2020","unstructured":"Lyu SQ, Yang YM, Zhu J et al (2020) The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials[J]. Platelets 31(8):971\u2013980. https:\/\/doi.org\/10.1080\/09537104.2020.1780205","journal-title":"Platelets"},{"issue":"21","key":"3224_CR38","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.jacc.2013.02.044","volume":"61","author":"AP Amin","year":"2013","unstructured":"Amin AP, Bachuwar A, Reid KJ et al (2013) Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status[J]. J Am Coll Cardiol 61(21):2130\u20132138. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.044","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"3224_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/tpj.2015.70","volume":"16","author":"I Fricke","year":"2015","unstructured":"Fricke I, C\u00e9spedes-Garro C, Rodrigues-Soares F et al (2015) Interethnic variation of CYP2C19 alleles, \u2018predicted\u2019 phenotypes and \u2018measured\u2019 metabolic phenotypes across world populations[J]. Pharmacogenomics J 16(2):113\u2013123. https:\/\/doi.org\/10.1038\/tpj.2015.70","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"3224_CR40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0040-1718729","volume":"121","author":"HK Kim","year":"2021","unstructured":"Kim HK, Tantry US, Smith SC Jr et al (2021) The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease [J]. Thromb Haemost 121(4):422\u2013432. https:\/\/doi.org\/10.1055\/s-0040-1718729","journal-title":"Thromb Haemost"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03224-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03224-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03224-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T08:03:35Z","timestamp":1641801815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03224-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3224"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03224-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}